pfmdr1 amplification associated with clinical resistance to mefloquine in West Africa: implications for efficacy of artemisinin combination therapies.
We describe here a clinical failure in the treatment with mefloquine of acute falciparum malaria contracted in Africa and associated with in vitro mefloquine resistance and pfmdr1 copy number amplification. This case raises the question of the presence and the evolution of this genotype in Africa, which is also known to alter the susceptibility to artemisinin combination therapy (ACT).
Witkowski
Benoit
B
Service de Parasitologie-Mycologie, Centre Hospitalier Universitaire de Toulouse, Université de Toulouse, Toulouse, France.
Iriart
Xavier
X
Soh
Patrice Njomnang
PN
Menard
Sandie
S
Alvarez
Muriel
M
Naneix-Laroche
Veronique
V
Marchou
Bruno
B
Magnaval
Jean-François
JF
Benoit-Vical
Françoise
F
Berry
Antoine
A
D000328:Adult; D000354:Africa, Western; D037621:Artemisinins / Q000494:pharmacology / Q000627:therapeutic use*; D004351:Drug Resistance; D004359:Drug Therapy, Combination / Q000379:methods; D018628:Gene Dosage; D006801:Humans; D020128:Inhibitory Concentration 50; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000469:parasitology*; D008297:Male; D015767:Mefloquine / Q000494:pharmacology / Q000627:therapeutic use*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*; D017211:Treatment Failure
D037621:Artemisinins; D015767:Mefloquine; D027425:ATP-Binding Cassette, Sub-Family C Proteins; C513498:Mdr1 protein, Plasmodium falciparum; C031327:artemisinin